In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Alexion acquires assets associated with Orphatec’s rare neonatal disease candidate

Executive Summary

Alexion Pharmaceuticals Inc. (specializes in complement inhibitors and monoclonal antibodies) has paid $3mm up front for patents and assets related to German biotech Orphatec Pharmaceuticals GMBH’s candidate for molybdenum cofactor deficiency (MoCD) Type A. The partners formed a research collaboration to advance this therapeutic.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies